IP Library Granted Patent US 7,910,622
Granted Patent B2
US 7,910,622 · App. 12/051,826 · Granted Mar 22, 2011

Modulation of bacterial quorum sensing with synthetic ligands

Assignee: Wisconsin Alumni Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,622
App. No.
12/051,826
Granted
Mar 22, 2011
Kind
B2
Abstract

The present invention provides compounds and methods for modulation of the quorum sensing of bacteria. In an embodiment, the compounds of the present invention are able to act as replacements for naturally occurring bacterial quorum sensing ligands in a ligand-protein binding system; that is, they imitate the effect of natural ligands and produce an agonistic effect. In another embodiment, the compounds of the present invention are able to act in a manner which disturbs or inhibits the naturally occurring ligand-protein binding system in quorum sensing bacteria; that is, they produce an antagonistic effect. The compounds of the present invention comprise N-acylated-homoserine lactones (AHLs) comprised of a wide range of acyl groups.

Claims (57)

1. A method comprising a step of contacting a quorum sensing bacteria with an amount of a compound effective for reducing virulence of said quorum sensing bacteria, said compound represented by the formula:

or a pharmaceutically acceptable salt or ester thereof,

wherein Y is selected from the group consisting of:

and wherein A is an alkoxy substituted aryl group.

2. The method of claim 1 wherein said bacteria is of a genus selected from the group consisting of Aeromonas, Agrobacterium, Burkholderia, Chromobacterium, Enterobacter, Erwinia, Escherichia, Nitrosomas, Obesumbacterium, Pantoea, Pseudomonas, Ralstonia, Rhisobium, Rhodobacter, Serratia, Vibrio, Xenorhabdus , and Yersinia.

3. The method of claim 2 wherein said bacteria is of a species selected from the group consisting of Aeromonas hydrophila, Aeromonas salmonicida, Agrobacterium tumefaciens, Burkholderia cepacia, Chromobacterium violaceum, Enterobacter agglomeran, Erwinia carotovora, Erwinia chrysanthemi, Escherichia coli, Nitrosomas europaea, Obesumbacterium proteus, Pantoea stewartii, Pseudomonas aureofaciens, Pseudomonas aeruginosa, Pseudomonas syringae, Ralstonia solanacearum, Rhisobium etli, Rhisobium leguminosarum, Rhodobacter sphaeroides, Serratia liquefaciens, Serratia marcescens, Vibrio anguillarum, Vibrio fischeri, Vibrio cholerae, Xenorhabdus nematophilus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia medievalis , and Yersinia ruckeri.

4. The method of claim 1 wherein the compound is represented by the formula:

or a pharmaceutically acceptable salt or ester thereof.

5. The method of claim 1 wherein the compound is present in a mixture comprising the compound and an antibiotic.

6. The method of claim 1 wherein A is an alkoxy substituted phenyl group.

7. The method of claim 6 wherein A is selected from the group consisting of:

8. The method of claim 1 wherein Y is

9. The method of claim 1 wherein Y is

10. The method of claim 1 wherein said step of contacting comprises disrupting or inhibiting biofilm formation.

11. The method of claim 10 wherein the compound is present in a mixture comprising the compound and an antibiotic.

12. The method of claim 8 wherein the compound is selected from the group consisting of:

13. The method of claim 8 wherein the compound is

14. The method of claim 13 wherein the compound is

15. The method of claim 8 wherein the compound is

16. The method of claim 8 wherein the compound is

17. The method of claim 8 wherein the compound is,

18. The method of claim 8 wherein the compound is

19. The method of claim 8 wherein the compound is

20. The method of claim 8 wherein the compound is

21. The method of claim 8 wherein the compound is

22. The method of claim 8 wherein the compound is

23. The method of claim 8 wherein the compound is

24. The method of claim 8 wherein the compound is

25. A method for treating an infection by quorum sensing bacteria comprising a step of administering to a subject having said infection an amount of a compound effective for reducing virulence of said quorum sensing bacteria, said compound represented by the formula:

or a pharmaceutically acceptable salt or ester thereof,

wherein Y is selected from the group consisting of:

and

A is an alkoxy substituted aryl group.

26. The method of claim 25 wherein the infection is by bacteria of a genus selected from the group consisting of Aeromonas, Agrobacterium, Burkholderia, Chromobacterium, Enterobacter, Erwinia, Escherichia, Nitrosomas, Obesumbacterium, Pantoea, Pseudomonas, Ralstonia, Rhisobium, Rhodobacter, Serratia, Vibrio, Xenorhabdus , and Yersinia.

27. The method of claim 26 wherein the infection is by bacteria of a species selected from the group consisting of Aeromonas hydrophila, Aeromonas salmonicida, Agrobacterium tumefaciens, Burkholderia cepacia, Chromobacterium violaceum, Enterobacter agglomeran, Erwinia carotovora, Erwinia chrysanthemi, Escherichia coli, Nitrosomas europaea, Obesumbacterium proteus, Pantoea stewartii, Pseudomonas aureofaciens, Pseudomonas aeruginosa, Pseudomonas syringae, Ralstonia solanacearum, Rhisobium etli, Rhisobium leguminosarum, Rhodobacter sphaeroides, Serratia liquefaciens, Serratia marcescens, Vibrio anguillarum, Vibrio fischeri, Vibrio cholerae, Xenorhabdus nematophilus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia medievalis , and Yersinia ruckeri.

28. The method of claim 25 wherein said treatment comprises disrupting or inhibiting biofilm formation.

29. The method of claim 28 wherein the compound is administered to the subject as a mixture comprising the compound and an antibiotic.

30. The method of claim 25 wherein the compound is represented by the formula:

or a pharmaceutically acceptable salt or ester thereof.

31. The method of claim 25 wherein the compound is present in a mixture comprising the compound and an antibiotic.

32. The method of claim 25 wherein A is an alkoxy substituted phenyl group.

33. The method of claim 32 wherein A is selected from the group consisting of:

34. The method of claim 25 wherein Y is

35. The method of claim 25 wherein Y is

36. The method of claim 34 wherein the compound is selected from the group consisting of:

37. The method of claim 34 wherein the compound is

38. The method of claim 37 wherein the compound is

39. The method of claim 34 wherein the compound is

40. The method of claim 34 wherein the compound is

41. The method of claim 34 wherein the compound is,

42. The method of claim 34 wherein the compound is

43. The method of claim 34 wherein the compound is

44. The method of claim 34 wherein the compound is

45. The method of claim 34 wherein the compound is

46. The method of claim 34 wherein the compound is

47. The method of claim 34 wherein the compound is

48. The method of claim 34 wherein the compound is

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 25, 2011
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026641/0706 →
CONFIRMATORY LICENSE Recorded Jul 21, 2011
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 026628/0157 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2008
From: BLACKWELL, HELEN E.; GESKE, GRANT D.; O'NEILL, JENNIFER C.
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 020844/0940 →
Continuity (4)
Provisional Application 60895598 · Mar 19, 2007
Provisional Application 60912345 · Apr 17, 2007
Provisional Application 60974026 · Sep 20, 2007
Related Publication 20080312319A1 · Dec 18, 2008